The role of delamanid in the treatment of drug-resistant tuberculosis

References

• World Health OrganisationGlobal Tuberculosis Report 2014GenevaWorld Health Organisation2014
   Google Scholar
• CorbettELWattCJWalkerNThe growing burden of tuberculosis: global trends and interactions with the HIV epidemicArch Intern Med200316391009102112742798
   PubMed Web of Science ®Google Scholar
• SloanDJDaviesGRKhooSHRecent advances in tuberculosis: new drugs and treatment regimensCurr Respir Med Rev20139320021024683386
   PubMedGoogle Scholar
• Streptomycin in Tuberculosis Trials Committee, Committee S in TTStreptomycin treatment of pulmonary tuberculosis: a medical research council investigationBMJ1948276978218890300
   PubMedGoogle Scholar
• LangeCAbubakarIAlffenaarJWTBNETManagement of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statementEur Respir J201444236324659544
   PubMed Web of Science ®Google Scholar
• PietersenEIgnatiusEStreicherEMLong-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort studyLancet201438399241230123924439237
   PubMed Web of Science ®Google Scholar
• O’DonnellMRPadayatchiNKvasnovskyCWernerLMasterIHorsburghCRTreatment outcomes for extensively drug-resistant tuberculosis and HIV co-infectionEmerg Infect Dis201319341642423622055
   PubMed Web of Science ®Google Scholar
• World Health OrganisationDrug-Resistant TB: Surveillance and Response Supplement Global Tuberculosis ReportGenevaWorld Health Organisation2014
   Google Scholar
• ShahNSRichardsonJMoodleyPIncreasing drug resistance in extensively drug-resistant tuberculosis, South AfricaEmerg Infect Dis20111751051321392446
   PubMed Web of Science ®Google Scholar
• UdwadiaZFTotally drug-resistant tuberculosis in India: who let the djinn out?Respirology20121774174222564108
   PubMed Web of Science ®Google Scholar
• VelayatiAAMasjediMRFarniaPEmergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in IranChest200913642042519349380
   PubMed Web of Science ®Google Scholar
• MiglioriGBDe IacoGBesozziGCentisRCirilloDMFirst tuberculosis cases in Italy resistant to all tested drugsEuro Surveill2007125E070517.117868596
   PubMedGoogle Scholar
• MaZLienhardtCMcIlleronHNunnAJWangXGlobal tuberculosis drug development pipeline: the need and the realityLancet20103752100210920488518
   PubMed Web of Science ®Google Scholar
• McIlleronHMeintjesGBurmanWJMaartensGComplications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndromeJ Infect Dis2007196supplS63S7517624828
   PubMedGoogle Scholar
• CohenJApproval of novel TB drug celebrated – with restraintScience2013339611613023307714
   PubMed Web of Science ®Google Scholar
• RyanNJLoJHDelamanid: first global approvalDrugs20147491041104524923253
   PubMed Web of Science ®Google Scholar
• AshtekarDRCosta-PeriraRNagrajanKVishvanathanNBhattADRittelWIn vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosisAntimicrob Agents Chemother19933721831868452346
   PubMed Web of Science ®Google Scholar
• NagarajanKNitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activityEur J Med Chem1989246631633
   Web of Science ®Google Scholar
• MatsumotoMHashizumeHTomishigeTOPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in micePLoS Med2006311e46617132069
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAssessment Report: DeltybaLondonEuropean Medicines Agency2013
   Google Scholar
• MukherjeeTBoshoffHNitroimidazoles for the treatment of TB: past, present and futureFuture Med Chem20113111427145421879846
   PubMed Web of Science ®Google Scholar
• GurumurthyMMukherjeeTDowdCSSubstrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazolesFEBS J2012279111312522023140
   PubMed Web of Science ®Google Scholar
• SaliuOYCrismaleCSchwanderSKWallisRSBactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosisJ Antimicrob Chemother200760599499817761500
   PubMed Web of Science ®Google Scholar
• SasakiHHaraguchiYItotaniMSynthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b] oxazolesJ Med Chem200649267854786017181168
   PubMed Web of Science ®Google Scholar
• DoiNDisratthakitACharacteristic antimycobacterial spectra of the novel anti-TB drug candidates OPC-67683 and PA-824InterscienceConference on Antimicrobial Agents and Chemotherapy (ICAAC)San Francisco, CA2006 Poster F1–F1377a
   Google Scholar
• OPC-67683Tuberculosis (Edinb)200888213213318486051
   PubMedGoogle Scholar
• MiyomotoGUnique PK profile of OPC-67683, a new potent anti-tuberculous drugIntersci Conf Antimicrob Agents ChemotherWashington, DC2005 Poster F-1466
   Google Scholar
• ShimokawaYSasaharaKYodaNMizunoKUmeharaKDelamanid does not inhibit or induce cytochrome p450 enzymes in vitroBiol Pharm Bull201437111727173525366478
   PubMed Web of Science ®Google Scholar
• NuermbergerELSpigelmanMKYewWWCurrent development and future prospects in chemotherapy of tuberculosisRespirology20101576477820546189
   PubMed Web of Science ®Google Scholar
• SinghRManjunathaUBoshoffHIPA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO releaseScience200832259061392139519039139
   PubMed Web of Science ®Google Scholar
• ChideyaSWinstonCAPeloquinCAIsoniazid, rifampin, etham-butol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from BotswanaClin Infect Dis2009481685169419432554
   PubMed Web of Science ®Google Scholar
• PasipanodyaJGSrivastavaSGumboTMeta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapyClin Infect Dis20125516917722467670
   PubMed Web of Science ®Google Scholar
• DiaconAHDawsonRHanekomMEarly bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patientsInt J Tuberc Lung Dis201115794995421682970
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyDeltyba: Summary of Product CharacteristicsLondonEuropean Medicines Agency2014
   Google Scholar
• SenousyBEBelalSIDraganovPVHepatotoxic effects of therapies for tuberculosisNat Rev Gastroenterol Hepatol2010754355620808293
   PubMed Web of Science ®Google Scholar
• De JagerRVan AltenaRHearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosisInt J Tuberc Lung Dis2002662262712102302
   PubMed Web of Science ®Google Scholar
• PaccalyAPetersenCPatilSAbsence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects9th International AIDS ConferenceWashington, DC2012 Abstract No WEPE043
   Google Scholar
• PetersenCDelamanid, a new drug for multi-drug resistant tuberculosis (MDR-TB), and efavirenz do not show clinically relevant drug interactions in healthy subjects52nd ICAACSan Francisco, CA2012 Poster abstract A-1255
   Google Scholar
• Van NiekerkCGinsbergAAssessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?Int J Tuberc Lung Dis2009131367137219861008
   PubMed Web of Science ®Google Scholar
• SloanDJCorbettELButterworthAEOptimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settingsJ Clin Microbiol2012502315232022573593
   PubMed Web of Science ®Google Scholar
• BurmanWJRip Van Winkle wakes up: development of tuberculosis treatment in the 21st centuryClin Infect Dis201050suppl 3S165S17220397944
   PubMed Web of Science ®Google Scholar
• ChanSLYewWWMaWKThe early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosisTuber Lung Dis199273133381326348
   PubMedGoogle Scholar
• DonaldPRSirgelFAVenterAThe early bactericidal activity of streptomycinInt J Tuberc Lung Dis20026869369812150481
   PubMed Web of Science ®Google Scholar
• DonaldPRSirgelFAVenterAThe early bactericidal activity of amikacin in pulmonary tuberculosisInt J Tuberc Lung Dis20015653353811409580
   PubMed Web of Science ®Google Scholar
• BothaFJSirgelFAParkinDPvan de WalBWDonaldPRMitchisonDAEarly bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosisS Afr Med J19968621551588619142
   PubMed Web of Science ®Google Scholar
• JindaniAAberVREdwardsEAMitchisonDAThe early bactericidal activity of drugs in patients with pulmonary tuberculosisAm Rev Respir Dis198012169399496774638
   PubMed Web of Science ®Google Scholar
• JohnsonJLHadadDJBoomWHEarly and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosisInt J Tuberc Lung Dis200610660561216776446
   PubMed Web of Science ®Google Scholar
• DietzeRHadadDJMcGeeBEarly and extended early bactericidal activity of linezolid in pulmonary tuberculosisAm J Respir Crit Care Med2008178111180118518787216
   PubMed Web of Science ®Google Scholar
• GlerMTSkripconokaVSanchez-GaravitoEDelamanid for mul-tidrug-resistant pulmonary tuberculosisN Engl J Med2012366232151216022670901
   PubMed Web of Science ®Google Scholar
• ZhangQLiuYTangSShaWXiaoHClinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in ChinaCell Biochem Biophys201367395796323546935
   PubMed Web of Science ®Google Scholar
• SkripconokaVDanilovitsMPehmeLDelamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisEur Respir J20134161393140023018916
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Development and Commercialization, IncSafety and Efficacy Trial of Delamanid for 6 Months in Patients with Multidrug Resistant Tuberculosis NLM identifier: NCT014246702011
   Google Scholar
• Otsuka Pharmaceutical Development and Commercialization, IncPharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients with Multidrug Resistant Tuberculosis NLM identifier: NCT018566342013
   Google Scholar
• Otsuka Pharmaceutical Development and Commercialization, IncA 6-Month Safety, Efficacy, and Pharmacokinetic Trial of Delamanid in Pediatric Patients with Multidrug Resistant Tuberculosis NLM identifier: NCT018599232013
   Google Scholar
• World Health OrganisationThe Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy GuidanceGenevaWorld Health Organisation2014
   Google Scholar
• MitchisonDAAssessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 monthsAm Rev Respir Dis19931474106210638466107
   PubMedGoogle Scholar
• DaviesGREarly clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activityTuberculosis (Edinb)201090317117620382567
   PubMed Web of Science ®Google Scholar
• GillespieSHCrookAMMcHughTDREMoxTB ConsortiumFour-month moxifloxacin-based regimens for drug-sensitive tuberculosisN Engl J Med201437117140907080012008
   Web of Science ®Google Scholar
• MerleCSFieldingKSowOBOFLOTUB/Gatifloxacin for Tuberculosis ProjectA four-month gatifloxacin-containing regimen for treating tuberculosisN Engl J Med2014371171588159825337748
   PubMed Web of Science ®Google Scholar
• JindaniAHarrisonTSNunnAJRIFAQUIN Trial TeamHigh-dose rifapentine with moxifloxacin for pulmonary tuberculosisN Engl J Med2014371171599160825337749
   PubMed Web of Science ®Google Scholar
• RustomjeeRLienhardtCKanyokTGatifloxacin for TB (OFLOTUB) Study TeamA Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosisInt J Tuberc Lung Dis200812212813818230244
   PubMed Web of Science ®Google Scholar
• World Health OrganisationCompanion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant TuberculosisGenevaWorld Health Organisation2014
   Google Scholar
• AungKJVan DeunADeclercqESuccessful “9-month Bangladesh regimen” for multidrug-resistant tuberculosis among over 500 consecutive patientsInt J Tuberc Lung Dis201418101180118725216831
   PubMed Web of Science ®Google Scholar
• PhillipsPPGillespieSHBoereeMInnovative trial designs are practical solutions for improving the treatment of tuberculosisJ Infect Dis2012205supplS250S25722448027
   PubMedGoogle Scholar
• EspositoSD’AmbrosioLTadoliniMERS/WHO tuberculosis consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid useEur Respir J201444381181524833763
   PubMed Web of Science ®Google Scholar
• LienhardtCRaviglioneMSpigelmanMNew drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the futureJ Infect Dis2012205supplS241S24922448022
   PubMedGoogle Scholar
• BurmanWJCottonMFGibbDMWalkerASVernonAADonaldPREnsuring the involvement of children in the evaluation of new tuberculosis treatment regimensPLoS Med200858e17618715115
   PubMed Web of Science ®Google Scholar
• Joint Formulary CommiteeBritish National Formulary68th edLondonBMJ Group and Pharmaceutical Press2014
   Google Scholar
• GruberKAccess sought to tuberculosis drug from nutraceutical companyNat Med201521210325642939
   PubMed Web of Science ®Google Scholar